MIOS Inhibitors
MIOS inhibitors, short for Mitochondrial Division Inhibitors, belong to a distinct chemical class renowned for their role in modulating cellular processes associated with mitochondrial dynamics. Mitochondria, often referred to as the powerhouse of the cell, undergo dynamic changes in shape and distribution through processes such as fission and fusion. MIOS inhibitors specifically target the machinery responsible for mitochondrial division, playing a crucial role in regulating the intricate balance between mitochondrial fragmentation and fusion. This class of compounds operates at the molecular level, interacting with key proteins involved in the division process, influencing the overall morphology of mitochondria within cells.
At the core of MIOS inhibitors' mechanism is their ability to impede the activity of proteins crucial for mitochondrial fission. By disrupting the normal course of mitochondrial division, these inhibitors impact the structural integrity of the organelle. The intricate dance between fission and fusion is vital for cellular health, influencing processes like energy production, apoptosis, and cellular stress responses. MIOS inhibitors, through their targeted modulation of mitochondrial dynamics, offer a valuable tool for researchers investigating the fundamental mechanisms governing cellular homeostasis. Understanding the nuances of how these inhibitors influence mitochondrial division sheds light on the intricate interplay between cellular compartments, providing insights into potential avenues for further exploration in cellular biology and biochemistry.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 can indirectly inhibit MIOS by disrupting the PI3K-AKT-mTOR signaling pathway. Since MIOS is a component of the GATOR2 complex that positively regulates the mTORC1 pathway, inhibition of PI3K and subsequent AKT signaling can reduce MIOS signaling activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that directly binds to the mTOR complex, which MIOS is known to regulate through the GATOR2 complex. The binding of Rapamycin to mTORC1 can lead to the reduced activity of MIOS as it inhibits downstream signaling of mTORC1. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is another mTOR inhibitor that can effectively inhibit both mTORC1 and mTORC2 complexes. Given that MIOS is involved in mTORC1 signaling through GATOR2, Torin 1 can lead to a decrease in MIOS-mediated signaling by inhibiting mTORC1 activity. | ||||||
WYE-125132 | 1144068-46-1 | sc-364651 sc-364651A | 10 mg 50 mg | $510.00 $1536.00 | ||
WYE-132 is a potent and selective inhibitor of mTOR. By inhibiting mTOR kinase activity, it impairs the mTORC1 signaling pathway. Since MIOS regulates mTORC1 signaling, WYE-132 would thus indirectly inhibit the functional activity of MIOS. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
An ATP-competitive inhibitor of mTOR, PP242 not only inhibits mTORC1 but also mTORC2, leading to broad inhibition of mTOR signaling. As a result, MIOS's role in regulating mTORC1 would be compromised, decreasing its functional activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a selective inhibitor of mTOR kinase activity, impacting both mTORC1 and mTORC2 signaling complexes. Through the inhibition of these complexes, AZD8055 would indirectly decrease MIOS signaling by preventing mTORC1's activation. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794 is a selective mTOR inhibitor that can block mTORC1 and mTORC2 pathways. By inhibiting these complexes, it can decrease the signaling activity of MIOS which regulates mTORC1. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $321.00 $1835.00 | ||
MLN0128 is a selective ATP-competitive mTOR kinase inhibitor that can impede both mTORC1 and mTORC2 signaling. Inhibition of these complexes will indirectly lead to decreased activity of MIOS due to its regulatory role over mTORC1. | ||||||
OSI-027 | 936890-98-1 | sc-364557 sc-364557A | 10 mg 50 mg | $437.00 $1186.00 | 1 | |
OSI-027 is a selective ATP-competitive inhibitor of mTORC1 and mTORC2. By inhibiting these complexes, OSI-027 can indirectly decrease the functional activity of MIOS, which is part of the GATOR2 complex that regulates mTORC1. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 is an inhibitor of the PI3K/Akt/mTOR pathway, particularly affecting the mTORC1 complex. As MIOS is involved in the regulation of mTORC1, the inhibition of this pathway by Palomid 529 leads to a reduction in MIOS activity. | ||||||